

April Abele Isaacson

Partner

Two Embarcadero Center
Suite 1900 , San Francisco , CA USA 94111
t 415.273.8306 | f 415.354.3519
aisaacson@kilpatricktownsend.com

Services

Asset Creation - Prosecution &
Counseling
Life Sciences Patent Disputes
FDA Regulation
Intellectual Property
ITC Section 337
Licensing, Transactions &
Monetization
Market Protection - Opinions &
Dispute Avoidance
Patent Due Diligence
Patent Litigation
Patents
Post-Grant Proceedings

Industries

Chemicals
Health & Life Sciences
Medical & Surgical Devices



April Abele Isaacson has over 25 years of experience as a trial lawyer and is a registered United States patent attorney. Her practice focuses on pharmaceutical, biotechnology, chemical, medical device and medical technology patent litigation, particularly Hatch-Waxman cases on behalf of drug innovators. April has tried cases in several federal district courts throughout the United States, as well as appeals before the Federal Circuit, representing both plaintiffs and defendants. April also provides counseling on patent and related regulatory issues faced by the biopharma industry, including patent portfolio strategy, litigation preparation and strategy, licensing, patent term extension strategy, and Orange Book patent listing and Use Code strategy, and provides opinions on issues of patentability/validity, freedom-to-operate, and loss of exclusivity.

April previously served for nearly five years as in-house counsel at a public specialty pharmaceutical company where she provided broad intellectual property and regulatory strategic counseling during all stages of product development and managed numerous Hatch-Waxman litigations. She also served as a partner at a major international law firm and at a predecessor firm to Kilpatrick Townsend.

April began her legal career as a U.S. Navy JAG Corps prosecutor where she won several high profile jury cases and earned multiple achievement medals and letters of commendation for superior service and leadership. Prior to attending law school, she was an HIV/AIDS research scientist at Boston Children's Hospital.

Experience

Representing a pharmaceutical company in Hatch-Waxman litigations concerning a drug for treatment of opioid-induced constipation.

Representing a pharmaceutical company in an adversarial patent action with a non-practicing patent holder.

Trial counsel for medical device innovator in patent infringement litigation concerning spinal deformity repair devices.

Representing radiosurgery device innovator.

*Counseled a pharmaceutical company in preparation for Hatch-Waxman litigations concerning a drug for early onset childhood epilepsy.

*Counseled a pre-commercial biopharmaceutical company on portfolio strategy and development partnerships.

*Represented a pharmaceutical company as in-house counsel in Hatch-Waxman litigation concerning a nasal spray product.

*Represented a pharmaceutical company as in-house counsel in Hatch-Waxman litigation concerning a drug for Parkinson's disease.

*Represented a pharmaceutical company in Hatch-Waxman litigation concerning a drug for treating diarrhea and irritable bowel syndrome.

*Represented a leading agricultural chemical company and a specialty pest control chemical manufacturer in a patent infringement action concerning patents relating to the pesticide fipronil.

*Represented a pharmaceutical company in a Hatch-Waxman litigation concerning a synthetic vitamin drug.

*Represented a manufacturer of biological and pharmaceutical products for animals in patent infringement litigation actions brought by an animal health company on patents related to vaccines, vaccine components, and recombinant DNA techniques for making vaccines.

*Represented leading portfolio medical technology company.

*Represented developer of innovative rapid point-of-care diagnostic tests and diabetes self-monitoring products.

*Represented designer and manufacturer of laser vision correction systems.

*Experience gained by attorney prior to joining Kilpatrick Townsend

Education



Mount Holyoke College A.B. Biological Sciences, *cum laude*

The University of Chicago M.S. Pharmacological and Physiological Sciences, Committee on Cellular and Molecular Physiology

Vanderbilt University School of Law J.D.

Admissions

California (1995)

District of Columbia (1997)

Court Admissions

U.S. Court of Appeals for the Federal Circuit

U.S. District Court for the Central District of California

U.S. District Court for the Eastern District of California

U.S. District Court for the Eastern District of Michigan

U.S. District Court for the Eastern District of Texas

U.S. District Court for the Northern District of California

U.S. District Court for the Southern District of California

U.S. Patent and Trademark Office

Professional & Community Activities

[MEMO|Medicine & Molecules](#), *The Kilpatrick Townsend Biopharma Industry Blog*, Co-Editor-in-Chief

U.S. Navy, Prosecutor/Officer-in-Charge, Criminal Defense and Legal Assistance Attorney (1995-1999 Active Duty; 1999-2003 Reserve)

CalVet Women Veterans Division, Member

San Francisco Intellectual Property Law Association, Member

American Intellectual Property Law Association, Member

Federal Circuit Bar Association, Member

Insights

[Events](#)

A Healthy Dose Of Federal Circuit Cases: Did 2021 Zoom Right By?

August 2, 2021



[News Releases](#)

Kilpatrick Townsend's 2021 Diversity & Inclusion Award Winners

July 19, 2021

[In The News](#)

Kimberlynn Davis and April Abele Isaacson Quoted by *Law360* re: "High Court Limit On Patent Challenges To Spur More Fights"

June 29, 2021

[In The News](#)

Stanford Bid for Gene Inheritance Patent Falls Short Again

March 26, 2021

[Publications](#)

"Curiouser and Curiouser!": Federal Circuit Affirms PTAB Patent-Ineligibility Decision Under Alice

March 17, 2021

[Publications](#)

Will There Be a Legislative Push to Reform Patent Eligibility Requirements During the Biden Administration?

March 12, 2021

[Perspectives](#)

Podcast | Sidebars by Kilpatrick Townsend

March 8, 2021

[Publications](#)

Biosimilars and the Biologics Price Competition and Innovation Act (BPCIA)

February 25, 2021

[Publications](#)

Cost-Containment Strategies for Patentees in Litigation

January 14, 2021

[Publications](#)

Pre-litigation Preparation and Strategy for Pharmaceutical Product Patents and Exclusivity

January 14, 2021



Alerts

What to Watch in 2021: Big Changes for Drug Companies in China

December 21, 2020

Publications

Compulsory Licensing To Cut Drug Costs Could Harm Public

December 18, 2020

Perspectives

Kilpatrick Townsend Veterans Day 2020 | April Abele Isaacson, Navy

November 10, 2020

In The News

Kilpatrick Townsend Welcomes April Abele Isaacson As Partner

October 23, 2020

In The News

Brian O'Reilly, Wab Kadaba, and April Abele Isaacson Quoted in *The Recorder*

October 16, 2020

In The News

On the Move: Tracking the Ins and Outs of California Lawyers

October 16, 2020

News Releases

Kilpatrick Townsend Lands National Life Sciences Patent Litigation Team in New York, San Francisco, and Seattle

October 14, 2020